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1. Introduction
Calcium phosphates  (CaP)  have  been  sought  as  biomaterials  for  reconstruction  of  bone
defect  in  maxillofacial,  dental  and  orthopaedic  applications  [1-31].  Calcium  phosphates
have  been  used  clinically  to  repair  bone  defects  for  many  years.  Calcium  phosphates
such as  hydroxyapatite  (Ca10(PO4)6(OH)2,  HAp),  fluorapatite  (Ca10(PO4)6F2,  FAp),  tricalci‐
um phosphate (Ca3(PO4)2, TCP), TCP-HAp composites and TCP-FAp composites are used
for medical  and dental  applications [3,  10-29].  In general,  this  concept is  determined by
advantageous  balances  of  more  stable  (frequent  by  hydroxyapatite  or  fluorapatite)  and
more resorbable (typically tricalcium phosphate) phases of calcium phosphates, while the
optimum ratios depend on the particular applications. The complete list of known calci‐
um phosphates,  including their  major  properties  (such,  the  chemical  formula,  solubility
data) is given in Table 1.  The detailed information about calcium phosphates,  their syn‐
thesis, structure, chemistry, other properties and biomedical applications have been com‐
prehensively reviewed recently in reference [24].
Calcium phosphate-based biomaterials and bioceramics are now used in a number of differ‐
ent applications throughout the body, covering all areas of the skeleton. Applications in‐
clude dental implants, percutaneous devices and use in periodontal treatment, treatment of
bone defects, fracture treatment, total joint replacement (bone augmentation), orthopedics,
cranio-maxillofacial reconstruction, otolaryngology and spinal surgery [32-35]. Depending
upon whether a bioresorbable or a bioactive material is desired, different calcium ortho‐
phosphates might be used.
© 2013 Sakka et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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In the past, many implantations failed because of infection or a lack of knowledge about the
toxicity of the selected materials. In this frame, the use of calcium phosphates is logical due
to their similarity to the mineral phase of bone and teeth [36-40]. However, according to
available literature, the first attempt to use calcium phosphates as an artificial material to re‐
pair surgically-created defects in rabbits was performed in 1920 [41]. More than fifty years
later, the first dental application of a calcium phosphate (erroneously described as TCP) in
surgically-created periodontal defects [42] and the use of dense HAp cylinders for immedi‐
ate tooth root replacement were reported [43]. Since Levitt et al. described a method of pre‐
paring an apatite bioceramics from FAp and suggested its possible use in medical
applications in 1969[44]. According to the available databases, the first paper with the term
‘‘bioceramics’’ in the abstract was published in 1971 [45], while those with that term in the
title were published in 1972 [46-47]. However, application of ceramic materials as prostheses
had been known before [48-49]. Further historical details might be found in literature [50].
Commercialization of the dental and surgical applications of Hap-based bioceramics occur‐
red in the 1980’s, largely through the pioneering efforts by Jarcho [51], de Groot [52] and Ao‐
ki [53]. Due to that, HAp has become a bioceramic of reference in the field of calcium
phosphates for biomedical applications. Preparation and biomedical applications of apatites
derived from sea corals (coralline HAp) [54–56] and bovine bone were reported at the same
time [57]. Since 1990, several other calcium phosphate cements have been developed [58-62],
injectable cements have been formulated [63], and growth factors have been delivered via
these cements [64]. The tetracalcium phosphate [TTCP: Ca4(PO4)2O] and dicalcium phos‐
phate anhydrous [DCPA: CaHPO4] system was approved in 1996 by the Food and Drug Ad‐
ministration (FDA) for repairing craniofacial defects in humans, thus becoming the first
TTCP–DCPA system for clinical use [65]. However, due to its brittleness and weakness, the
use of TTCP–DCPA system was limited to the reconstruction of non-stress-bearing bone
[66-67]. To expand the use of TTCP–DCPA system to a wide range of load-bearing maxillo‐
facial and orthopedic repairs, recent studies have developed natural biopolymers that are
elastomeric, biocompatible and resorbable [68]. Calcium phosphates in a number of forms
and compositions are currently either in use or under consideration in many areas of den‐
tistry and orthopedics. For example, bulk materials, available in dense and porous forms,
are used for alveolar ridge augmentation, immediate tooth replacement and maxillofacial re‐
construction [35, 69]. Other examples include orbital implants (Bio-Eye) [70-71], increment
of the hearing ossicles, spine fusion and repair of bone defects [72-73]. In order to permit
growth of new bone onto bone defects, a suitable bioresorbable material should fill the de‐
fects. Otherwise, in-growth of fibrous tissue might prevent bone formation within the de‐
fects [69-73]. Today, a large number of different calcium phosphate bioceramics for the
treatment of various defects are available on the market.
The performance of living tissues is the result of millions of years of evolution, while the
performance of acceptable artificial substitutions those man has designed to repair damaged
hard tissues are only a few decades old. Archaeological findings exhibited in museums
showed that materials used to replace missing human bones and teeth have included animal
or human (from corpses) bones and teeth, shells, corals, ivory (elephant tusk), wood, as well
as some metals (gold or silver). For instance, the Etruscans learned to substitute missing
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teeth with bridges made from artificial teeth carved from the bones of oxen, while in ancient
Phoenicia loose teeth were bound together with gold wires for tying artificial ones to neigh‐
boring teeth.
Compound Acronym Formula Ca/P pKs a
Monocalcium phosphate
monohydrate
MCPM Ca(H2PO4)2 .H2O 0.5 1.14
Monocalcium phosphate anhyrous MCPA Ca(H2PO4)2 0.5 1.14
Dicalcium phosphate dihydrate DCPD CaHPO4 .2H2O 1 6.59
Dicalcium phosphate anhydrous DCPA CaHPO4 1 6.90
Aporphous calcium phosphates ACP CaxHy(PO4)z .nH2O
n = 3-4.5; 12-20%H2O
1.2-2.2 b
Octacalcium phosphate OCP Ca8(HPO4)2(PO4)4 .5H2O 1.33 96.6
α- Tricalcium phosphate α-TCP α- Ca3(PO4)2 1.5 25.5
β- Tricalcium phosphate β-TCP β- Ca3(PO4)2 1.5 28.9
Calcium-deficient Hydroxyapatite CDHAp Ca10-x(HPO4)x(PO4)6-x(OH)2-x (0 < x < 1) 1.5-1.67 85
Hydroxyapatite HAp Ca10(PO4)6(OH)2 1.67 116.8
Fluorapatite FAp Ca10(PO4)6F2 1.67 120
Oxapatite OAp Ca10(PO4)6O 1.67 69
Tetracalcium phosphate TTCP Ca4(PO4)2O 2 38-44
(a): Solubility at 25°C (pKs = -logKs);
(b) : Cannot be measured precisely.
Table 1. Calcium phosphates and their major properties [3, 24]
Calcium phosphates are established materials for the augmentation of bone defects. They
are available as allogenic, sintered materials. Unfortunately, these calcium phosphates ex‐
hibit relatively poor tensile and shear properties [74]. In practice, the strength of the calcium
phosphate cements is lower than that of bone, teeth, or sintered calcium phosphate biocer‐
amics [75] and, together with their inherent brittleness, restricts their use to non-load bear‐
ing defects [76] or pure compression loading [74]. Typical applications are the treatment of
maxillo-facial defects or deformities [77] and cranio facial repair [78] or augmentation of
spine and tibial plateau [74]. A successful improvement of the mechanical properties would
significantly extend the applicability of calcium phosphates [79] and can be achieved by
forming composite materials [80]. Second phase additives to the calcium phosphate compo‐
sites have been either fibrous reinforcements or bioinert oxides that interpenetrate the po‐
rous matrix.
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Hydroxyapatite and other calcium phosphates bioceramics are important for hard tissue re‐
pair because of their similarity to the minerals in natural bone, and their excellent biocom‐
patibility and bioactivity [81-86]. When implanted in an osseous site, bone bioactive
materials such as HAp and other CaP implants and coatings provide an ideal environment
for cellular reaction and colonization by osteoblasts. This leads to a tissue response termed
osteoconduction in which bone grows on and bonds to the implant, promoting a functional
interface [81, 84, 87]. Extensive efforts have significantly improved the properties and per‐
formance of HAp and other CaP based implants [88-92]. Calcium phosphate cements can be
molded or injected to form a scaffold in situ, which can be resorbed and replaced by new
bone [93, 65-67]. Chemically, the vast majority of calcium phosphate bioceramics is based on
HAp, β-TCP, α-TCP and/or biphasic calcium phosphate (BCP), which is an intimate mixture
of either β-TCP - HAp [94-100] or α-TCP - HAp [101-111]. The preparation technique of
these calcium phosphates has been extensively reviewed in literature [1, 4, 37, 102-104].
When compared to both β- and α-TCP, HAp is a more stable phase under physiological con‐
ditions, as it has a lower solubility (Table 1) [37, 109-110]. Therefore, the BCP concept is de‐
termined by the optimum balance of a more stable phase of HAp and a more soluble TCP.
Due to a higher biodegradability of the β - or α -TCP component, the reactivity of BCP in‐
creases with the TCP-HAp the increase in ratio. Thus, in vivo bioresorbability of BCP can be
controlled through the phase composition [95]. As implants made of calcined HAp are
found in bone defects for many years after implantation, bioceramics made of more soluble
calcium phosphates is preferable for the biomedical purposes [94-110]. HAp has been clini‐
cally used to repair bone defects for many years [3]. However, Hap has poor mechanical
properties [3]. Their use at high load bearing conditions has been restricted due to their brit‐
tleness, poor fatigue resistance and strength.
The main reason behind the use of β-TCP as bone substitute materials is  their chemical
similarity to the mineral component of mammalian bone and teeth [1-3]. The application
of tricalcium phosphate as a bone substitute has received considerable attention, because
it  is  remarkably  biocompatible  with  living  bodies  when  replacing  hard  tissues  and  be‐
cause it has biodegradable properties [1-29]. Consequently, β-TCP has been used as bone
graft substitutes in many surgical fields such as orthopedic and dental surgeries [3, 11-12,
16-17].  This  use  leads  to  an  ultimate  physicochemical  bond  between  the  implants  and
bone-termed osteointegration. Even so, the major limitation to the use of β-TCP as load-
bearing biomaterial  is  their  mechanical  properties  which make it  brittle,  with  poor  fati‐
gue resistance [3, 10, 21-29]. Moreover, the mechanical properties of tricalcium phosphate
are  generally  inadequate  for  many  load-carrying  applications  (3  MPa  –  5  MPa)  [3,  10,
20-29].  Its  poor  mechanical  behaviour  is  even more  evident  when used to  make highly
porous ceramics and scaffolds. Hence, metal oxides ceramics, such as alumina (Al2O3), ti‐
tania (TiO2) and some oxides (e.g. ZrO2, SiO2) have been widely studied due to their bioi‐
nertness,  excellent  tribological  properties,  high  wear  resistance,  fracture  toughness  and
strength as well as relatively low friction [19, 21-22, 29-31]. However, bioinert ceramic ox‐
ides having high strength are used to enhance the densification and the mechanical prop‐
erties  of  β-TCP.  In  this  chapter,  we  will  try  to  improve  the  strength  of  β-TCP  by
introducing a bioinert oxide like alumina. This is because there are few articles reporting
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the toughening effects of an inert oxide (like alumina (Al2O3)) on the mechanical proper‐
ties of β-TCP [22, 27,  29].  Alumina has a high strength and is bio-inert with human tis‐
sues  [19,  22,  27,  29].  In  order  to  improve  the  biocompatibility  of  alumina  and  the
strength  of  tricalcium phosphate  effectively,  and in  order  to  search  for  an  approach  to
produce high performances of alumina-tricalcium phosphate composites,  β-TCP is intro‐
duced with different percentages in the alumina matrix. The aim of our study is to elabo‐
rate and characterize the TCP-Al2O3 composites for biomedical applications.
This chapter proposes to study the sintering of the alumina-tricalcium phosphate compo‐
sites at various temperatures (1400°C, 1450°C, 1500°C, 1550°C and 1600°C) and with differ‐
ent percentages of β-TCP (10 wt%, 20 wt%, 40 wt% and 50 wt%). The characterization of
biomaterials will be realized by using dilatometry analysis, differential thermal analysis
(DTA), X-ray diffraction (XRD), magic angle spinning nuclear magnetic resonance (MAS
NMR), scanning electron microscopy analysis (SEM) and by using the mechanical proper‐
ties, such as rupture strength (σr) of these biomaterials.
2. Materials and methods
The synthesized tricalcium phosphate and alumina (Riedel-de Haёn) were mixed in order to
prepare biomaterial composites. The β-TCP powder was synthesized by solid-state reaction
from calcium carbonate (CaCO3) and calcium phosphate dibasic anhydrous (CaHPO4) [27].
Stoichiometric amounts of high purity powders such as CaHPO4 (Fluka, purity ≥ 99%) and
CaCO3 (Fluka, purity ≥ 98.5%), were sintered at 1000°C for one hour to obtain the β-TCP ac‐
cording to the following reaction:
( ) ( ) ( ) ( ) ( ) ( )4 3 3 4 2 222                          CaHPO s CaCO s Ca PO s H O g CO g+ ® + + (1)
The β-TCP and the alumina powders were mixed in an agate mortar. The powder mixtures
were milled in ethanol for 24 hours. After milling, the mixtures were dried in a rotary vac‐
uum evaporator and passed through a 70-mesh screen. After drying the powder mixtures at
80°C for 24 hours, they were molded in a cylinder having a diameter of 20 mm and a thick‐
ness of 6 mm, and pressed under 150 MPa. The green compacts were sintered at various
temperatures for different lengths of time in a vertical furnace (Pyrox 2408). The heating rate
is 10°C min-1. The size of the particles of the powder was measured by means of a Micromer‐
itics Sedigraph 5000. The specific surface area (SSA) was measured using the BET method
and using N2 as an adsorption gas (ASAP 2010) [112]. The primary particle size (DBET) was
calculated by assuming the primary particles to be spherical:
 6 /  BETD Sr= (2)
where ρ is the theoretical density and S is the surface specific area.
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The microstructure of the sintered compacts was investigated using the scanning electron
microscope (Philips XL 30) on the fractured surfaces of the samples. The grains’ mean size
was measured directly using SEM micrographs. The powder was analyzed by using Xray
diffraction (XRD). The Xray patterns were recorded using the Seifert XRD 3000 TT diffrac‐
tometer. The Xray radiance was produced by using CuKα radiation (λ = 1.54056 Å). The
crystalline phases were identified with the powder diffraction files (PDF) of the Internation‐
al Center for Diffraction Data (ICDD). Linear shrinkage was determined using dilatometry
(Setaram TMA 92 dilatometer). The heating and cooling rates were 10°C min-1 and 20°C
min-1, respectively. Differential thermal analysis (DTA) was carried out using about 30 mg of
powder (DTATG, Setaram Model). The heating rate was 10°C min-1. The 31P and 27Al magic
angle spinning nuclear magnetic resonance (31P MAS NMR) spectra were run on a Brucker
300WB spectrometer. The 31P and 27Al observational frequency were 121.49 MHz and 78.2
MHz, respectively. The 31P MAS-NMR chemical shifts were referenced in parts per million
(ppm) referenced to 85 wt% H3PO4. The 27Al MAS-NMR chemical shifts were referenced to a
static signal obtained from an aqueous aluminum chloride solution.
The Brazilian test was used to measure the rupture strength of biomaterials [113-114]. The
rupture strength (σr) values were measured using the Brazilian test according to the equa‐
tion:
2
r
P
D ts
×= P × × (3)
where P is the maximum applied load, D the diameter, t the thickness of the disc and σr the
rupture strength (or mechanical strength).
3. Results and discussion
3.1. Characterization of different powders
The X-ray diffraction analysis of β-TCP powder and α-alumina powder are presented in Fig‐
ure 1. As it can be noticed from this figure, the X-ray diffraction pattern of tricalcium phos‐
phate powder reveals only peaks of β-TCP (ICDD data file no. 70-2065) without any other
phase (Figure 1a). Consequently, the XRD pattern obtained from the alumina powder illus‐
trates α phase peaks relative to ICDD data file no. 43-1484 (Figure 1b).
The 31P MAS-NMR solid spectrum of the tricalcium phosphate powder is presented in Fig‐
ure 2a. We observe the presence of several peaks of tetrahedral P sites (at 0.36 ppm, 1.46
ppm and 4.83 ppm), while there are other peaks (at -7.43 ppm, -9.09 ppm and -10.35 ppm)
which reveal a low quantity of calcium pyrophosphate which was formed during the prepa‐
ration of the β-TCP.
The 27Al MAS-NMR solid spectrum of the alumina powder is presented in Figure 2b. We no‐
tice the presence of two peaks which are characteristic of aluminum: one peak at 7.36 ppm
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corresponding to octahedral Al sites (AlVI) and the other at 37.36 ppm which corresponds to
pentahedral Al sites (AlV). The results obtained for 31P MAS-NMR and 27Al MAS-NMR are
similar to those previously reported by different authors [14, 22, 25-28, 31].
Figure 1. The XRD patterns of: (a) β-TCP powder and (b) α-Al2O3 powder
Figure 2. The 31P MAS-NMR spectra of: (a) β-TCP and the 27Al MAS-NMR spectra of: (b) α-Al2O3
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The experimental characteristics of the different powders used in this study are illustrated in
Table 2. Table 2 summarizes the SSA, the DTA measurements, the sintering temperature
and the theoretical density of the different powders. The powder particles are assumed to be
spherical; the size of the particles can be calculated using Eq. (2). The results from the aver‐
age grain size obtained by the SSA (DBET) and from the average grain size obtained by gran‐
ulometric repartition (D50) are presented in Table 2. Compared with those of the β-TCP
powder, the grains of the alumina powder have a dense morphology. These (DBET) values
obtained by the SSA do not correspond to those obtained from the granulometric repartition
(Table 2). The discrepancy may be due to the presence of agglomerates which are formed
during the preparation of the β-TCP powder at 1000°C.
Compounds SSA (m2/g)
± 1.0
DBET (µm)
± 0.2
D50 (µm)a
± 0.2
DTA measurements
(endothermic peak)
T(°C)b dc
TCP 0.70 2.79 6 1100°C-1260°C (β → α)
1470°C (α → α’)
1000 - 1300 3.070 (β)
2.860 (α)
Alumina 2.87 0.53 3 - 1400 - 1600 3.98 (α)
a : mean diameter,
b : sintering temperature domain,
c : theoretical density
Table 2. Characteristics of the powders used in the study
Differential thermal analysis studies of the different powders used in this study detected a
potential phase change during the sintering process. The DTA thermogram of β-TCP, α-
Al2O3 and different Al2O3 - TCP composites are presented in Figure 3. The DTA curve of alu‐
mina reported no process relative to the sintering temperature (Figure 3a). Figure 3b shows
the DTA curve of β-TCP. The DTA thermogram of β-TCP shows two endothermic peaks,
relative to the allotropic transformations of tricalcium phosphate (Figure 3b). The peak be‐
tween 1100°C – 1260°C is related to the first allotropic transformation of TCP (β to α), while
the last peak at 1470°C is related to the second allotropic transformation of TCP (α to α’). As
a matter of fact, this result is similar to the result previously reported by Destainville et al.
and Ben Ayed et al. [9, 14]. Figure 3c shows the DTA curve of Al2O3-50 wt% TCP compo‐
sites. This DTA curve is practically similar to the one shown in Figure 3b. Indeed, the DTA
thermogram of the composites also shows two endothermic peaks. Figure 3 (d), (e) and (f)
illustrate the DTA curves of Al2O3–40 wt% TCP composites, Al2O3–20 wt% TCP composites
and Al2O3–10 wt% TCP composites, respectively. The DTA thermograms of each composites
show only one endothermic peak between 1100°C and 1260°C, which are relative to the allo‐
tropic transformation of TCP (β to α). In these curves, we notice that the endothermic peak
relative to a second allotropic transformation of TCP (α to α’) has practically disappeared
when the percentage of the alumina increases in the Al2O3 - TCP composites (Figure 3(d), (e)
and (f)).
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Figure 3. DTA curves of (a) α-Al2O3, (b) β-TCP, (c) Al2O3 – 50 wt% TCP composites, (d) Al2O3 – 40 wt% TCP composites,
(e) Al2O3 – 20 wt% TCP composites and (f) Al2O3 – 10 wt% TCP composites
Figure 4 shows the dilatometric measurements of the different powders used in this study
(β-TCP, α-Al2O3 and Al2O3 - TCP composites). A large sintering domain was observed for
the three powders (β-TCP, alumina and composites). The sintering temperature of the initial
powder began at about 900°C and at about 1400°C for the β-TCP and alumina (Figure 4a-b
and Table 2). The sintering temperature of Al2O3-50 wt% TCP composites began at 1100°C
(Figure 4c). It is to be noted that the presence of 50 wt% TCP in the alumina matrix decreases
the sintering temperature of the alumina by around 300°C (Figure 4c). This variation of the
sinterability is relative to the difference between the physicochemical compositions of these
powders and the mixture of their different composites.
3.2. The mechanical properties of alumina–tricalcium phosphate composites
The influence of the sintering temperature on the rupture strength of Al2O3-TCP composites
is shown in Figure 5. The mechanical resistance of Al2O3-TCP composites is studied at vari‐
ous temperatures (1400°C, 1450°C, 1500°C, 1550°C, 1600°C) for one hour with different per‐
centages of β-TCP (50 wt%, 40 wt%, 20 wt% and 10 wt%). Thus, Figure 5 illustrates the
rupture strength of the Al2O3-TCP composites relative to the percentages of the alumina and
the sintering temperature. Consequently, the rupture strength of Al2O3 mixed with 10 wt%
β-TCP reached its maximum value when sintered at 1600°C for one hour; it then decreased
with the increase of this percentage. This is how the rupture strength of the Al2O3-10 wt%
TCP composites reached 13.5 MPa.
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Figure 4. Linear shrinkage versus temperature of: (a) β-TCP, (b) α-Al2O3 and (c) Al2O3 – 50 wt% TCP composites
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Figure 5. The rupture strength of the TCP-Al2O3 composites sintered for 1 hour at various temperatures: (a) 1400°C,
(b) 1450°C, (c) 1500°C, (d) 1550°C and (e) 1600°C
Figure 6 shows the evolution of the rupture strength of the Al2O3 - 10 wt% TCP composites
sintered at various temperatures (1500°C, 1550°C and 1600°C) for different sintering times (0
min, 30 min, 60 min and 90 min). The optimum value of the rupture strength was indeed
obtained after an hour-long sintering process at 1600°C. Thus, the mechanical resistance of
the samples reached 13.5 MPa.
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Figure 6. The rupture strength of the Al2O3–10 wt% TCP composites sintered for different lengths of time at various
temperatures: (a) 1500°C, (b) 1550°C and (c) 1600°C
In this study, we showed that the presence of different amounts of alumina in the β-TCP im‐
proves the mechanical properties of Al2O3-TCP composites. In fact, the mechanical proper‐
ties of Al2O3-10 wt% TCP composites reached the optimum value by being sintered at
1600°C for one hour. Thus, the rupture strength of these composites reached 13.5 MPa. Table
3 displays several examples of the mechanical properties of the calcium phosphates and the
bone tissues. In comparison, we notice that the properties of Al2O3-10 wt% TCP composites
are close to those of pure β-TCP, pure Fap and TCP-33.16 wt% Fap composites, which have
a rupture strength of 5.3 MPa, 14 MPa and 13.7 MPa, respectively [15, 21, 25]. However, the
mechanical properties of our composites are more closely comparable to those of the pure
Fap and the TCP–33.16 wt% Fap composites (Table 3). Generally, the values found for the
mechanical strength of our composites are not identical to those in Table 3, because the au‐
thors have used different mechanical modes other than the Brazilian test. In addition, many
factors influence the mechanical properties of the samples such as: the use of particular ini‐
tial powders as well as the conditions of the treatment process.
The sintering of materials is a complex process, involving the evolution of the microstruc‐
ture through the action of several different transport mechanisms such as: surface diffusion,
evaporation- condensation, grain boundary diffusion [3]. However, producing dense TCP–
Al2O3 composites with a fine uniform microstructure through the sintering process does not
seem to be a routine process because the β-TCP has a lower sinterability and a lower sinter‐
ing temperature than those of pure alumina.
Mechanical Properties of Biomaterials Based on Calcium Phosphates and Bioinert Oxides…
http://dx.doi.org/10.5772/53088
33
Materials σr (a) (MPa) σc (b) (MPa) σf (c) (MPa) References
β-TCP 4-6 - 92 [21,27]
Fap 10-14 - - [15]
Hap - 5.35 - [115]
TCP - 75 wt% Al2O3 8.60 - - [27]
TCP – 26.52 wt% Fap 9.60 - - [21]
TCP – 26.52 wt% Fap- 5 wt% Al2O3 13.60 - - [22]
TCP – 33.16 wt% Fap 13.70 - - [25]
Hap – TCP (40:60) - 4.89 - [115]
Al2O3 - 26.5 wt% Fap 21.7 - - [31]
Cortical bone - 130-180 50-150 [1, 2]
Cancellous bone - 2-12 - [1, 2]
(a): Rupture strength (Brazilian test),
(b): compressive strength
(c): Flexural strength.
Table 3. Literature examples of the mechanical properties of calcium phosphates bioceramics and bone tissues
3.3. Characterization of alumina-tricalcium phosphate composites after the sintering
process
Figure 7 shows the 31P MAS-NMR spectra of the Al2O3-TCP composites obtained after the
sintering process for 1 hour at 1550°C with different percentages of β-TCP (50 wt%, 40 wt%,
20 wt% and 10 wt%). The addition of 50 wt% Al2O3 to the TCP matrix shows the presence of
several peaks which are assigned to the tetrahedral environment of P sites (1.03 ppm; 1.93
ppm; 3.50 ppm and 4.84 ppm) (Figure 7a). In fact, the increasing of the percentage of alumi‐
na in the TCP matrix decreases the number of the tetrahedral phosphorus site peaks which
are reduced to a large single peak with 90 wt% alumina (Figure 7 b-d). Moreover, the tetra‐
hedral environment of the phosphorus in tricalcium phosphate is not changed after the sin‐
tering process with different percentages of alumina. But the effect of the addition of
alumina to the β-TCP matrix provokes the structural rearrangement of the coordination of
phosphorus in β-TCP. Similar results were previously reported in literature [14, 26-27, 31].
The 27Al MAS-NMR spectra of Al2O3-TCP composites sintered for 1 hour at 1550°C with dif‐
ferent percentages of β-TCP (50 wt%, 40 wt%, 20 wt% and 10 wt%) are shown in Figure 8.
The chemical shifts at 35 ppm and at 7.3 ppm indicate the presence of octahedral Al sites
(AlVI) and pentahedral Al sites (AlV), respectively. The peak of pentahedral Al sites increases
with the increase of the percentage of alumina in the Al2O3-TCP composites (Figure 8 b-8d).
We notice especially the appearance of another octahedral Al peak at 18.6 ppm for alumina
sintered with 40 wt% and 20 wt% of β-TCP (Figure 8 b-d). The aluminum in the alumina is
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primarily in one pentahedral Al site (35 ppm) and in one octahedral Al site (7.3 ppm) (Fig‐
ure 8e). For the alumina sintered with different percentages of β-TCP (50 wt%, 40 wt%, 20
wt% and 10 wt%), the spectra show two octahedral aluminum environments: AlO6 at about
7.3 ppm and at 18.6 ppm (Fig 8b-d). Indeed, the intensity of the octahedral signal at 18.6
ppm increases with the percentage of alumina. The estimated concentrations of AlO5 and
AlO6 are reported in Table 4. During the sintering process, the aluminum in the Al2O3-TCP
composites provokes the structural rearrangement of the coordination of aluminum. Similar
results were provisionally reported by different authors [22, 27, 31]. Indeed, these authors
show that the coordination of the aluminum in octahedral sites was forced to change into
another coordination in pentahedral sites [31]. The same authors point out that the structur‐
al rearrangement of the coordination of aluminum was probably produced by the formation
of calcium aluminates which was produced after the sintering process and the reaction be‐
tween calcium phosphates and alumina [31]. In conclusion, the 31P magic angle scanning nu‐
clear magnetic resonance analysis of different composites reveals the presence of tetrahedral
P sites, while the 27Al magic angle scanning nuclear magnetic resonance analysis shows the
presence of both octahedral and pentahedral Al sites.
Figure 7. The 31P MAS-NMR spectra of the Al2O3-TCP composites sintered for 1 hour at 1550°C with different percen‐
tages of β-TCP: (a) 50 wt%, (b) 40 wt%, (c) 20 wt% and (d) 10 wt%
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Figure 8. The 27Al MAS-NMR spectra of the Al2O3-TCP composites sintered for 1 hour at 1550°C with different percen‐
tages of β-TCP: (a) 50 wt%, (b) 40 wt%, (c) 20 wt%, (d) 10 wt% and (e) 0 wt%
Compounds AlO5 (%) AlO6 (Type 1) (%) AlO6 (Type 2) (%)
δ (ppm) 30-40 7 18
TCP - 50 wt % Al2O3 0.50 99.50
TCP - 60 wt % Al2O3 15.38 65.37 19.25
TCP - 80 wt % Al2O3 19.71 67.81 12.48
TCP- 90 wt % Al2O3 14.85 73.71 11.44
Al2O3 1.40 98.60
Table 4. Properties of pentahedral and octahedral Al sites in the Al2O3-TCP composites sintered with different
percentages of β-TCP at various temperatures for 1 hour
Figure 9 presents XRD patterns of Al2O3-TCP composites sintered at 1550°C for 1 hour with
different percentages of β-TCP. Besides, the spectra show the characteristic peaks of β-TCP
(ICDD data file no. 70-2065) and α- Al2O3 (ICDD data file no. 43-1484). This analysis shows
that the peak of alumina is predominant in the elaboration of any composite.
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Figure 9. The XRD patterns of the Al2O3-TCP composites sintered at 1550°C for 1 hour with different percentages of β-
TCP: (a) 50 wt%, (b) 40 wt%, (c) 20 wt%, (d) 10 wt% and (e) 0 wt%
The SEM technique helps to investigate the texture and porosity of any biomaterial. Figure
10 shows the fracture surface of the Al2O3-TCP composites sintered at 1550°C for 1 hour
with different percentages of β-TCP. These micrographs show the coalescence between β-
TCP grains produced with all the percentages of added alumina (Figure 10 a-d). The sam‐
ples sintered with 50 wt%, 40 wt% and 20 wt% β-TCP present cracks and an important
intragranular porosity (Figure 10 a-c). This result is a proof of the fragility of the composites
elaborated with the different percentages of alumina as shown in Figure 10a-c. In fact, the
microstructure of the composites shows different cracks relative to the allotropic transfor‐
mation of TCP (β to α) (Figure 10 a-c). But the intensity of the cracks in the composites de‐
creases with the increase in the percentage of β-TCP (Figure 10 a-d). Thus, the absence of
micro-cracking and the reduction of the sizes of the pores in the Al2O3-10 wt% TCP compo‐
sites explain the increase in the rupture strength of the samples (Figure 10 d1-d2). Indeed, the
composites present excellent mechanical properties and a good aptitude for sinterability
(Figure 10 d1-d2). The SEM micrographs of the alumina sintered without β-TCP shows an in‐
tergranular porosity (Figure 10e).
The effects of the sintering temperature on the microstructure of the Al2O3-10 wt% TCP com‐
posites are presented in Figure 11. The SEM micrographs show the coalescence between the
grains with the increase of the sintering temperature. At 1500°C, the samples present an im‐
portant intergranular porosity (Figure 11a). The microstructure of Al2O3-10 wt% TCP com‐
posites sintered at 1550°C shows a continuous phase relative to β-TCP phases and small-
sized grains relative to the alumina phases (Figure 11b). Furthermore, at 1600°C, the
boundaries between grains are evident in the micrographs (marked with arrows in Figure
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11c), confirming the best mechanical resistance of Al2O3-10 wt% TCP composites in this tem‐
perature and with the addition of 10 wt% β-TCP (Figure 11c). In fact, the continuous phases
in addition to the formed spherical pores prove that a liquid phase has appeared at 1600°C
relative probably to the allotropic transformation of the β-TCP. This similar result was ob‐
served by Bouslama and colleagues [25].
Figure 10. The SEM micrographs of the Al2O3 - TCP composites sintered at 1550°C for 1 hour with different percen‐
tages of β-TCP: (a) 50 wt%, (b) 40 wt%, (c) 20 wt%, (d1-d2) 10 wt% and (e) 0 wt%.
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Figure 11. The SEM micrographs of the Al2O3-10 wt% TCP composites sintered for 1 hour at: (a) 1500°C, (b) 1550°C
and (c) 1600°C.
The results of the microstructural investigations of Al2O3-10 wt% TCP composites sintered at
1600°C for different lengths of time (0 min, 30 min, 60 min and 90 min) are shown in Figure
12. These micrographs reveal the influence of different lengths of time on the microstructur‐
al developments during the sintering process at 1600°C. The microstructure of the samples
leads to the formation of important cracks of different sizes with composites sintered for 0
min, 30 min and 90 min (Figure 12 ba-b and 12d). The continuous phases are relative to the
β-TCP phase while the grains of a small size are relative to the alumina phase (Figure 12 ba-
b and 12d). In Figure 12c, we notice the coalescence between the grains after the sintering
process for 60 min confirming the best mechanical resistance in these conditions.
Furthermore, the sintering behavior of the Al2O3-TCP composites has been studied relative
to the β-TCP content. It has been shown that alumina should be used in order to prevent the
β-α transition of the tricalcium phosphate during the sintering process. At any rate, the re‐
sults obtained in the present work would be valuable in the performance of Al2O3 - TCP
composites resembling bone tissue engineering (Table 3). In fact, our preliminary tests indi‐
cated that the rupture strength of Al2O3-TCP composites is from 2 to 14 MPa. The optimum
value of the Al2O3 - 10 wt% TCP composites sintered at 1600°C for one hour reached 13.5
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MPa. This is true for the values of calcium phosphates fabricated by conventional techni‐
ques [116] and is close to a cancellous bone (2-12 MPa) [1-2, 117].
Figure 12. SEM micrographs of the Al2O3 - 10 wt% TCP composites sintered at 1600°C for: (a) 0 min, (b) 30 min, (c) 60
min and (d) 90 min.
According to the authors’ best knowledge, the highest values of the mechanical characteris‐
tics for different samples are detailed in Table 3. As it can be seen from this table, the various
techniques used to prepare dense sintered bioceramics affect the final density, as well as the
composition of the phase and, consequently, the final mechanical properties of samples. The
Al2O3 - 10 wt% TCP composites show high rupture strength, which is in concordance with
the other results [10, 15, 21, 25-27, 29]. The rupture strength obtained for TCP-Al2O3 compo‐
sites is from 2 to 14 MPa, within the values reported in the literature (Table 3). Moreover, the
wide variation in the reported rupture strength of the composites is due to the synthesis
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route of the β-TCP powder, the size of its particle as well as to its density; it is also due to
the application of different processing parameters.
At first, the objective of this work was to characterize the mechanical properties of alumina –
TCP composites produced after the sintering process. A sintering stage appears to be of
great importance to produce biomaterials with the required properties. Several processes oc‐
cur during the sintering process of tricalcium phosphate and bioinert oxide. Firstly, the TCP
powders are synthesized by solid reaction. Secondly, alumina – TCP powders are sintered
for production of dense bioceramics with subsequent shrinkage of the samples. Thirdly, the
mechanical properties of alumina–TCP composites are accompanied by a concurrent in‐
crease in grain size and a formation of cracks in the alumina sintered with different percen‐
tages of TCP (20 wt%, 40 wt% and 50 wt%). Besides, sintering causes the toughening and the
increase of the mechanical strength of alumina–10 wt% TCP composites. An extensive study
on the effect of the sintering temperature and time on the properties of alumina–TCP com‐
posites revealed a correlation between these parameters and density, porosity, grain size,
chemical composition and strength of different composites. The degree of densification and
mechanical properties of alumina–TCP composites appeared to depend on the sintering
temperature and the duration of sintering. Alumina–TCP powders can be pressed and sin‐
tered up to theoretical density at 1400°C–1600°C. Processing them with higher percentage of
TCP (20 wt%, 40 wt% and 50 wt%) may lead to exaggerated grain growth and formation of
cracks because of the formation of α-TCP at higher temperatures. Indeed, the allotropic
transformation of TCP is a function of the sintering temperature. The presence of cracks in
the alumina–TCP composites is reported to inhibit the mechanical properties. A definite cor‐
relation between mechanical strength and grain size in sintered alumina–TCP composites
was found: the strength started to decrease at lower sintering temperature and with higher
percentage of TCP (20 wt%, 40 wt% and 50 wt%). The sintering process of alumina – 10 wt%
TCP composites makes it possible to decrease the grain size and achieve higher densities.
This leads to finer microstructures, higher thermal stability of alumina–10 wt% TCP compo‐
sites and subsequently better mechanical properties of the prepared bioceramics composites.
The mechanical properties of alumina – TCP composites is from 2 to 14 MPa. Generally, the
mechanical properties of samples increase with the decrease in grain size. In fact, the me‐
chanical strength of alumina–10 wt% TCP composites reaches a maximum value with the
decrease in the size of the grains of composites. The optimum measured value of the
strength of the alumina–10 wt% TCP composites was 13.5 MPa. This value is compared to
those of cancellous bone. Similar values for porous HAp are in the ranges of 2-10 MPa [118].
Generally, variations of mechanical properties of samples are caused by a statistical nature
of the strength distribution, influence of remaining microporosity, grain size, presence of
impurities and Ca/P ratio [118].
In conclusion, an interfacial reaction between β-TCP and alumina has been studied in the
nanocomposites of Al2O3-TCP. It was found that the alumina did not completely react with
the β-TCP and did not form calcium aluminates. Moreover, it has been shown that the alu‐
mina prevents the formation of cracks in the microstructure of composites containing 10 wt
% of β-TCP. The mechanical characteristics should be taken into consideration in order to
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better assess the relationship between the processing conditions, the microstructural design
as well as the mechanical response.
4. Conclusions
The biomaterials of alumina-tricalcium phosphate composites have been characterized by
using MAS NMR, XRD and SEM analysis after the sintering process. The effect of β-TCP ad‐
ditive on the alumina matrix was observed in different thermal analyses: dilatometry analy‐
sis and DTA analysis. The mechanical properties have been investigated by the Brazilian
test. This investigation has allowed us to define the sintering temperature and the percent‐
age of added alumina for which β-TCP should have an optimal densification and better me‐
chanical properties. This study has also allowed us to summarize the effect of the sintering
temperature and the length of sintering time on the mechanical properties of the Al2O3-TCP
composites. The produced Al2O3-TCP composites with different percentages of β-TCP (50
wt%; 40 wt%; 20 wt% and 10 wt%) exhibited much better mechanical properties than the re‐
ported values of β-TCP without alumina. The Al2O3-TCP composites showed a higher rup‐
ture strength at 1600°C, which certainly increased with the alumina content and reached the
optimum value with 90 wt%. However, no cracks were observed in the microstructure of the
composites which contained this percentage of alumina. This is due to the allotropic trans‐
formation of the tricalcium phosphate. The partial or reversal transformation of tricalcium
phosphate (β to α or α to α’) during the cooling period could induce a residual stress within
the dense bioceramics, marking it much more brittle. Accordingly, the optimum perform‐
ance of alumina-tricalcium phosphate composites achieved 13.5 MPa. Furthermore, the best
mechanical properties of the composites were obtained after the sintering process at 1600°C
for 1 hour. With different weight rations of tricalcium phosphate: alumina (50:50, 40:60 and
20:80), the performance of the composites was hindered by the formation of both cracks and
intragranular porosity.
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